About: BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.42 (+0.29%)
BCTX NASDAQ Briacell Therapeutics Corp
Briacell Therapeutics Corp share price
Atividade de preço de BCTX
Último preço
$ 3,420
Variação (24h)
0,01 USD (0,29%)
Volume
6.70K
Volume (média 4 sem.)
-
Abertura
$ 3,47
Variação do dia
$ 3,38 - $ 3,64
Fechamento anterior
$ 3,41
Último negócio
23 Oct, 2:18 pm GMT+0
Atrasado
23 Oct, 2:18 pm GMT+0
BCTX price performance
Atrasado
23 Oct, 2:18 pm GMT+0
quote.marketSignals